Alembic Pharma up by 2 per cent, receives USFDA approval for olmesartan medoxomil
DSIJ Intelligence / 25 Apr 2017
Alembic Pharma received the US Food and Drugs Association's final approval for the production of olmesartan medoxomil tablets on April 25, 2017.
Alembic Pharma received the US Food and Drugs Association's final approval for the production of olmesartan medoxomil tablets on April 25, 2017.
The approval from USFDA will facilitate the pharma major to produce 5 mg, 20 mg, 40mg olmesartan medoxomil tablets and 20/12.5 mg, 40/12.5 mg and 40/25mg olmesartan medoxomil with hydrochlorothiaside tablets. The olmesartan medoxomil tablets are used for the treatment of hypertension.
Recently, the pharma company also received the approval from USFDA for 10 mg, 20 mg and 40 mg vilazodona hydrochloride tablets. The vilazodona hydrochloride tablets are likely to be used for the treatment of major depressive disorder (MDD).
Alembic Pharma is trading at Rs 620, up by 2.21 per cent on April 25, 2017 at 11:38 hrs IST on the BSE.
Alembic Pharma has a total of 54 ANDA approvals, with 47 approved and 7 tentative approvals, from the USFDA.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.